Braveheart Bio Surges 66% on Nasdaq Debut, Fueling Phase 3 Push for Camzyos Rival

Braveheart Bio (BRVE) closed at $29.80 on its first day of Nasdaq trading August 6, a 66% pop from the $18 IPO price that values the cardiac drug developer at roughly $1.9 billion. The company raised $382.5 million by selling 21.25 million shares, upsizing the deal by 27% after pricing above the $15 to $17 range.

The proceeds fund BHB-1893, an oral cardiac myosin inhibitor licensed from China’s Hengrui Pharma for $65 million upfront in 2025. Cardiac myosin inhibitors reduce the excessive contraction of heart muscle that drives hypertrophic cardiomyopathy (HCM), a genetic condition affecting roughly 1 in 500 people where the heart wall thickens and impairs blood flow. Braveheart has allocated $90 million to start a Phase 3 trial in obstructive HCM (oHCM) later this year and another $100 million for a Phase 3 study in non-obstructive HCM (nHCM) in the first half of 2027. The drug is positioned as next-generation: Hengrui’s Phase 2 data showed rapid onset of action with minimal impact on left ventricular ejection fraction, an advantage over first-generation cardiac myosin inhibitors.

The HCM market is expanding rapidly. Bristol Myers Squibb’s Camzyos, the only approved cardiac myosin inhibitor in the US, generated $416 million in Q2 2026 revenue, up 60% year over year. Cytokinetics’ Myqorzo (aficamten) is the second entrant and reported positive Phase 3 data in nHCM in May 2026 — a result that makes Braveheart’s nHCM study a three-way race rather than a two-horse field. There is no FDA-approved treatment for nHCM yet, and the first company to file in that indication could capture a patient population roughly equal in size to the obstructive form.

Braveheart joins a busy August IPO window. It follows Attovia Therapeutics’ $289 million upsized IPO earlier this week, and the strong debut signals that public investors remain eager to fund late-stage cardiometabolic assets in categories where large pharma has already proven commercial demand.

The risk: BHB-1893 has Phase 2 data from Hengrui’s original Chinese program, but the registrational trials have not started. Camzyos will have a multi-year head start, and Myqorzo could expand into nHCM before Braveheart’s trial reads out. Hengrui dependency, both for the molecule and the existing clinical data package, is the other overhang. The $65 million license deal gave Braveheart a clinical-stage asset without the discovery cost, but it also means the company does not control the underlying IP. Investors are betting that $382.5 million and an experienced management team can execute faster than the incumbents can lock down the market.